HLTRF News and Press, HLS Therapeutics Inc From 06/10/20

HLS Therapeutics Confirms Annual Shareholders' Meeting Canada NewsWire TORONTO, ON, June 10, 2020 TORONTO, ON , June 10, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and ...

HLS Therapeutics to Present at the Jefferies Virtual Healthcare Conference Canada NewsWire TORONTO, June 1, 2020 TORONTO , June 1, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system ...

HLS Therapeutics to Become Distributor of the Saladax MyCare™ Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents Canada NewsWire TORONTO, June 1, 2020 The MyCare Insite is a point-of-care (POC) device that uses just a single drop of...

HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa® (Icosapent Ethyl) against COVID-19 Canada NewsWire TORONTO, May 21, 2020 TORONTO , May 21, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical co...

HLS Therapeutics ( OTCPK:HLTRF ): Q1 GAAP EPS of $0.00. More news on: HLS Therapeutics Inc., Earnings news and commentary, Tech stocks news, Read more ...

HLS Therapeutics Announces Q1 2020 Financial Results Canada NewsWire TORONTO, May 7, 2020 Revenue of $13.9 million , Adjusted EBITDA of $6.1 million and Cash from Operations of $5.3 million Launched Vascepa® in the Canadian market Vascepa added to Health ...

HLS Therapeutics to Host Q1 2020 Financial Results Conference Call Canada NewsWire TORONTO, April 30, 2020 TORONTO , April 30, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2020 financial results by press rel...

HLS Therapeutics Comments on U.S. District Court Decision on Amarin Patents Canada NewsWire TORONTO, March 31, 2020 TORONTO , March 31, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervo...

HLS Therapeutics Announces Fourth Quarter and Fiscal 2019 Financial Results Canada NewsWire TORONTO, March 19, 2020 Revenue of $54.2 million , Adjusted EBITDA of $31.6 million and Cash from Operations of $26.4 million Received approval from Health Canada for Vasce...

HLS Therapeutics to Host Q4 and Fiscal 2019 Financial Results Conference Call Canada NewsWire TORONTO, Feb. 27, 2020 TORONTO , Feb. 27, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervo...